- Home
- ALXO vs BUUU Comparison
ALXO vs BUUU Comparison
Compare ALXO & BUUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- BUUU
- Stock Information
- Founded
- ALXO 2015
- BUUU 2017
- Country
- ALXO United States
- BUUU Hong Kong
- Employees
- ALXO N/A
- BUUU N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- BUUU Services-Misc. Amusement & Recreation
- Sector
- ALXO Health Care
- BUUU Consumer Discretionary
- Exchange
- ALXO Nasdaq
- BUUU Nasdaq
- Market Cap
- ALXO 58.9M
- BUUU 68.1M
- IPO Year
- ALXO 2020
- BUUU 2025
- Fundamental
- Price
- ALXO $1.06
- BUUU $7.04
- Analyst Decision
- ALXO Strong Buy
- BUUU
- Analyst Count
- ALXO 6
- BUUU 0
- Target Price
- ALXO $3.30
- BUUU N/A
- AVG Volume (30 Days)
- ALXO 1.7M
- BUUU 149.9K
- Earning Date
- ALXO 11-06-2025
- BUUU 01-01-0001
- Dividend Yield
- ALXO N/A
- BUUU N/A
- EPS Growth
- ALXO N/A
- BUUU N/A
- EPS
- ALXO N/A
- BUUU 0.04
- Revenue
- ALXO N/A
- BUUU $5,754,120.00
- Revenue This Year
- ALXO N/A
- BUUU N/A
- Revenue Next Year
- ALXO N/A
- BUUU N/A
- P/E Ratio
- ALXO N/A
- BUUU $182.21
- Revenue Growth
- ALXO N/A
- BUUU 64.23
- 52 Week Low
- ALXO $0.40
- BUUU $3.67
- 52 Week High
- ALXO $2.36
- BUUU $7.80
- Technical
- Relative Strength Index (RSI)
- ALXO 54.74
- BUUU N/A
- Support Level
- ALXO $1.06
- BUUU N/A
- Resistance Level
- ALXO $1.27
- BUUU N/A
- Average True Range (ATR)
- ALXO 0.12
- BUUU 0.00
- MACD
- ALXO -0.02
- BUUU 0.00
- Stochastic Oscillator
- ALXO 32.26
- BUUU 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.